Articles On Noxopharm (ASX:NOX)

Australian clinical-stage drug development company Noxopharm (ASX:NOX) has announced that its DARRT-2 Phase 2 clinical trial has commenced with patient enrolment in the US.

The company believes that DARRT-treatment has the potential to revolutionise cancer treatment by reducing cancer through the abscopal response without many of the unwanted side effects, cost limitations and logistical challenges associated...

Noxopharm (ASX:NOX) has received Notices of Allowance from patent offices in Australia and Europe covering the use of idronoxil (the active ingredient in Veyonda) as a chemo-enhancing drug.

“If we can improve the performance of ICIs by the addition of Veyonda, it could make a massive impact, improving outcomes for cancer patients worldwide. It is exciting that this study is now underway in Australia, and we look forward to upd...

Wall Street gains as Tesla breaks US$1 trillion market cap US stocks rose overnight, led by a surge in Tesla which ripped higher by over 12% after receiving an order of 100,000 vehicles from car rental company Hertz. Tesla has joined other...

The Noxopharm Ltd (ASX: NOX) share price is edging higher this afternoon and is currently trading up 2.8% at 55 cents apiece. Shares in the drug development company are on the move after it released a key announcement regarding its lead dr...

Noxopharm (NOX) is granted Australian and European patents for its use of Veyonda to achieve safer chemotherapy The patent allows dosages of chemotherapy to be lowered to safer levels through the company’s drug candidate without compromisi...

"A high proportion of cancer patients are deprived of the benefits of chemotherapies because of toxic side-effects. Other patients either are too ill or too elderly or just unwilling to even start chemotherapy. That is the gap that we see V...

The ASX 200 Health Index (XHJ) is up by 0.80% at the time of writing, compared to the broader index which is higher by 0.7%. Notices from both the Australian and European Patent Offices have been received by Noxopharm (ASX:NOX), relating to...

The company is building a pipeline of drugs based on a unique and proprietary technology platform for large markets of unmet medical needs.

Australian clinical-stage drug development company Noxopharm (ASX:NOX) has announced that the US patent office has allowed claims relating to the use of a combination of its Veyonda and radiotherapy.

“We see the allowance of this patent application as a major win for the company in our goal of seeing DARRT therapy become a mainstream cancer treatment,” says CEO & MD.

The clinical-stage drug development company focused on the treatment of cancer and cytokine release syndrome is going into the new financial year in a strong cash position, enabling it to proceed with its exciting Four Pillars Oncology Prog...

Shares in drug company Noxopharm (ASX:NOX) climbed by around 4% this morning following the release of the company’s annual report. Along with the numbers, NOX also detailed the ongoing clinical development of Veyonda (idronoxil) as an adjuv...

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

The discovery of idronoxil's anti-inflammatory mechanism adds a high-profile and potentially high-value drug target for the company’s subsidiary Pharmorage’s emerging pipeline.

Its partnership with Hudson Institute of Medical Research, NOX has also led to an important discovery about the anti-inflammatory mechanism of action of idronoxil, the active ingredient in Veyonda®.

The Noxopharm Ltd (ASX: NOX) share price has been a strong performer on Monday. The clinical-stage drug development company’s shares were up as much as 13% to 63 cents at one stage today. The Noxopharm share price has since pulled back and...

IDT Australia (ASX:IDT) jumped more than 20% after announcing that it has formalised activities with the Australian Government to potentially assist with the production of a COVID-19 vaccine. There was recent media interest surrounding a mR...

Another red day for the ASX to close out the week. The ASX 200 closed 0.05% down from yesterday at 7,461 points, 2.2% lower than a week ago. The ASX Emerging Companies Index meanwhile dropped 2.09%, closing at 2,187 points which is over 5%...

The broader ASX continued its losing streak, shedding another 0.5% while the benchmark ASX 200 closed at 7,465 points, which is 2.2% lower than last Friday’s close. Health and consumer discretionary goods were rays of sunshine with gains of...

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

The clinical-stage drug development company’s collaboration with the US National Cancer Institute will run for an initial 12-month term, with the subsequent brain cancer program supported by a fully-costed budget.

Clinical-stage drug development company Noxopharm (ASX:NOX) has announced a formal collaboration with the National Cancer Institute within the US National Institutes of Health in the quest for more effective treatments of brain canc...

The clinical-stage drug development company will team up with an arm of the National Institutes of Health as it investigates a new family of anti-cancer drugs.

Wall Street mixed despite blowout jobs numbers US stock market were mixed on Friday, despite stronger than expected employments figures in the US. The Dow Jones rose by 0.41%, S&P 500 by 0.17% – both closing at record highs – while tech...

The S&P/ASX200 closed up Thursday, gaining 7.90 points or 0.11% to 7,511.10 and setting a new 100-day high. The top performing stocks in this index were NIB Holdings Limited (ASX:NHF)  Nuix Limited (ASX:NXL), up 3.05% and 2.75% respecti...

It now sees Veyonda having a major commercial future in the rapidly growing field of radioligand therapy, not just in prostate cancer, but across the broad cancer spectrum. 

ASX 200 health stocks index (XHJ) rose by 0.23% this morning, compared to the broader index which rose by 0.11%. Micro cap medical device company dorsaVi (ASX:DVL) took the limelight this morning, jumping by 12% after saying that it has ext...

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

IRIS Metals is set to become the latest Kookynie entrant to join the ASX boards, with its sights set on following the recent exploration successes other companies have had in the Kookynie mining camp. The company’s portfolio includes teneme...

Noxopharm is studying its Veyonda® drug candidate across a wide range of medical disciplines, with activity pursued across its oncology, COVID-19, septic shock, chronic inflammatory and autoimmune diseases portfolio.

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

It has an exciting pipeline of drugs under development and believes its novel technology platform is “one of the most exciting and valuable platforms” in the pharmaceutical industry.

With a key regulatory approval in place, Noxopharm is a step closer to starting a multi-national trial on patients with progressive, metastatic prostate, breast or lung cancers using a higher dose of its Veyonda® drug candidate.

Australian clinical-stage drug development company Noxopharm (ASX:NOX) has announced that the US FDA has granted Investigational New Drug approval to the DARRT-2 study.

The clinical-stage drug development company believes, if a patent is granted, it will support its ambition to make Veyonda a standard of care drug in combination with major cancer therapies.

Shares in Noxopharm Ltd (ASX: NOX) are gaining today following the company’s announcement of a notice of allowance for an important European patent. At the time of writing, the Noxopharm share price is 64 cents – 7.56% higher than its prev...

The Phase Two trial will broaden the scope of studies into a potential cancer treatment using a higher dose of its Veyonda® drug candidate.

The Noxopharm Ltd (ASX: NOX) share price is falling this afternoon. This comes after the company released an update about its DARRT-2 clinical trial. At the time of writing, Noxopharm shares are swapping hands for 69 cents apiece, down 1.4...

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

The company is more than one drug – the business is a drug pipeline based on a novel technology platform that it sees meeting a range of unmet needs of key current interest to the global pharmaceutical industry.

Summary The S&P/ASX200 is trading 5.20 points higher to 7265.30 by the afternoon. The index scaled a new intra-day high of 7282.3, before easing back. Healthcare, Industrials and Consumer Staples stocks gained over 1% each. ...

Noxopharm welcomes this outcome given its recent LuPIN trial data showing even stronger survival outcome when Lu-PSMA-617 is combined with Veyonda®.

The Noxopharm Ltd (ASX: NOX) share price is on course to end the week on a positive note. In morning trade, the clinical-stage drug development company’s shares are up 3% to 72 cents. This means the Noxopharm share price now up over 50% sin...

Summary The ASX 200 closed lower by 19 points or 0.27% at 7142.60. The Australian dollar and bond yields rise after the RBA policy decision. The RBA kept interest rates steady at record lows to support the economic growth. Austral...

The Noxopharm Ltd (ASX: NOX) share price went gangbusters today after the company released a new report about its flagship drug, Veyonda. Shares in the biotech closed trade 22% higher at 74 cents a share. Lets take a closer look at what pr...